Rosuvastatin Doses: 5 mg, 10 mg, 20 mg, and 40 mg Explained

Rosuvastatin is one of the most potent cholesterol-lowering medications available, and its four standard doses each occupy a distinct place on the risk-benefit spectrum. At 5 mg it delivers a meaningful reduction in LDL cholesterol for people who need moderate lowering or who are sensitive to side effects; at 10 mg it becomes the workhorse dose for most adults with high cholesterol; at 20 mg it shifts into high-intensity territory; and at 40 mg it pushes for the maximum effect the drug can deliver, though with trade-offs worth understanding. The differences between these doses go well beyond “more drug, more effect,” and the choice among them involves your baseline cholesterol numbers, cardiovascular risk, ancestry, kidney function, and what other medications you take.

Why Rosuvastatin Is Unusually Potent

All statins work by blocking the same liver enzyme responsible for manufacturing cholesterol. Rosuvastatin stands apart because it forms a greater number of binding interactions with that enzyme and has a particularly high affinity for its active site. It is also relatively hydrophilic, meaning it is selectively taken up by liver cells rather than drifting into muscle or other tissues. On top of that, rosuvastatin has the longest half-life of any statin and is only minimally broken down by the liver’s main drug-metabolizing system, which reduces the potential for interactions with other medications processed by the same pathway.¹ Its poor penetration into non-liver tissues like blood-vessel lining cells and fibroblasts is part of what makes it liver-selective.²

These properties explain why rosuvastatin achieves bigger cholesterol drops at lower milligram doses than most of its competitors. A 10 mg tablet of rosuvastatin is not equivalent to 10 mg of atorvastatin or simvastatin; it is considerably more powerful milligram for milligram.

How Much Each Dose Lowers Cholesterol

The landmark head-to-head comparison is the STELLAR trial, which randomly assigned over 2,400 patients to rosuvastatin, atorvastatin, simvastatin, or pravastatin at various doses for six weeks. Across dose ranges, rosuvastatin 10 to 40 mg reduced LDL cholesterol by about 8% more than atorvastatin at equivalent doses, 12 to 18% more than simvastatin, and 26% more than pravastatin. Rosuvastatin also raised HDL (“good”) cholesterol by roughly 8 to 10%, compared with 2 to 7% for the other statins. Cholesterol goals set by major treatment guidelines were reached by 82 to 89% of patients on rosuvastatin 10 to 40 mg, versus 69 to 85% on atorvastatin 10 to 80 mg.³

Additional analysis from the same trial showed that rosuvastatin reduced non-HDL cholesterol (a measure that captures more of the harmful lipid particles) by 42 to 51% across its dose range, compared with 34 to 48% for atorvastatin and 26 to 42% for simvastatin. The 20 mg dose of rosuvastatin produced the highest increase in apolipoprotein A-I, a protein that reflects HDL function.⁴

What this means in practical terms: rosuvastatin 5 mg typically lowers LDL by roughly 38 to 42%, 10 mg by about 45 to 47%, 20 mg by around 50 to 52%, and 40 mg by about 55% or slightly more. Each step up roughly follows the “rule of six” that applies to all statins: doubling the dose gets you an additional 6% or so of LDL reduction, not another full-sized drop. So the jump from 5 mg to 10 mg buys more than the jump from 20 mg to 40 mg, which is why clinicians sometimes add a second drug rather than maximizing the statin dose.

High-Dose Rosuvastatin and Plaque Regression

One of the most striking findings in the rosuvastatin story is that 40 mg daily can actually shrink the fatty plaques inside coronary arteries, not just slow their growth. The ASTEROID trial treated 349 patients with rosuvastatin 40 mg for two years and measured plaque volume with ultrasound probes threaded into the coronary arteries. The drug lowered LDL to an average of about 61 mg/dL and raised HDL by roughly 15%, and every measure of plaque burden shrank significantly.⁵⁶

A Japanese study called COSMOS found similar results with lower doses. Patients started at 2.5 mg and could be titrated up to 20 mg. Even at these more moderate levels, LDL dropped by about 39% and HDL rose by about 20%, and plaque volume shrank by roughly 5% over the study period.⁷ The COSMOS results matter because they suggest plaque regression is achievable without pushing to the maximum 40 mg dose, especially when the starting LDL is brought down far enough.

Cardiovascular Events and the JUPITER Trial

The case for rosuvastatin in people who do not yet have heart disease but carry elevated inflammation markers was made by the JUPITER trial, which remains one of the most influential statin trials ever conducted. Nearly 18,000 apparently healthy men and women with elevated C-reactive protein (an inflammation marker) but normal LDL cholesterol were given rosuvastatin 20 mg or a placebo. Rosuvastatin cut LDL levels by half and dropped C-reactive protein by 37%. The combined rate of heart attack, stroke, hospitalization for unstable chest pain, revascularization procedures, and cardiovascular death was cut by roughly 44%. Heart attacks alone were cut by about 54%, strokes by about 48%, and even death from any cause fell by about 20%.⁸

JUPITER was stopped early because the benefit was so clear, which is worth noting because early stopping tends to make treatment effects look larger than they would in a longer trial. Still, it firmly established that the 20 mg dose provides substantial protection even in people whose LDL would not traditionally have flagged them for treatment.

Kidney Signals at Higher Doses

When rosuvastatin was first approved, regulators noticed slightly higher rates of blood and protein in the urine compared with other statins. The clinical significance of this has been debated for two decades, and the picture is more nuanced than a simple warning label suggests.

A dedicated comparison of rosuvastatin 40 mg versus simvastatin 80 mg found that proteinuria (protein in the urine at a detectable level) occurred in about 1.3% of people on rosuvastatin 40 mg versus 0.3% on simvastatin 80 mg. The protein was predominantly of tubular origin, meaning it came from the kidney’s filtering tubes rather than from damage to the filtering membrane, and it was transient. Blood creatinine levels stayed stable, indicating no actual decline in kidney function.⁹ A large retrospective analysis of more than 40,600 participants in the rosuvastatin clinical development program also found that kidney event rates did not differ between rosuvastatin and placebo, or between rosuvastatin 40 mg and 10 mg, even in patients with pre-existing conditions like heart failure, high blood pressure, or reduced kidney function.¹⁰

However, a newer real-world study painted a somewhat more cautious picture. Compared with atorvastatin, rosuvastatin was associated with a slightly increased risk of blood in the urine and proteinuria in a dose-dependent manner, and a slightly higher risk of kidney failure requiring dialysis or transplant. The cardiovascular benefits were similar between the two drugs. The researchers found that 44% of patients with severe chronic kidney disease were prescribed a higher dose of rosuvastatin than the FDA-recommended maximum of 10 mg for that population.¹¹ The practical takeaway: for most people with healthy kidneys, the kidney signals at standard doses are clinically trivial. For people with severe kidney disease, the 10 mg ceiling that the FDA recommends is there for a real reason, and it is being widely ignored in practice.

The New-Onset Diabetes Question

All statins nudge blood sugar upward, and rosuvastatin is no exception. The question is how much, and whether it scales with dose. A large meta-analysis covering more than 113,000 patients found a gradient in diabetes risk across different types and doses of statins, with higher doses carrying a numerically higher risk than moderate ones for each individual drug.¹²

A meta-analysis of randomized trials in older adults put numbers on the intensity divide: low-to-moderate-intensity statin therapy increased the rate of new diabetes diagnoses by about 10% compared with placebo, while high-intensity therapy increased it by about 36%.¹³ A Korean nationwide cohort study looking specifically at rosuvastatin found a clear dose-dependent pattern: new-onset diabetes occurred in about 2.8% of those on 5 mg, 5.5% on 10 mg, and 8.3% on 20 mg.¹⁴

These numbers deserve context. The people most likely to develop diabetes on a statin are those who already have pre-diabetes or metabolic risk factors; the statin is not causing diabetes from scratch so much as accelerating an existing trajectory. And in every major trial, the cardiovascular benefits of the statin far outweigh the diabetes risk. But if you are borderline on blood sugar, your doctor has a real reason to prefer 5 or 10 mg over 20 or 40 mg when the cholesterol math allows it.

Why Your Ancestry Can Influence the Right Dose

The FDA label for rosuvastatin recommends that clinicians consider starting Asian patients at 5 mg rather than the standard 10 mg. This recommendation is based on pharmacokinetic studies showing that people of Asian descent can have meaningfully higher drug exposure at the same dose. A study of Chinese, Malay, and Asian-Indian subjects found that drug exposure (measured by area under the curve) was roughly 1.6 to 2.3 times higher compared with White subjects, and peak blood levels were 1.7 to 2.4 times higher, even when all participants lived in the same environment and had the same genetic variant profile for one key transporter gene.¹⁵

A separate study found that the area under the curve for rosuvastatin was about 86% higher in Chinese subjects and 55% higher in Japanese subjects compared with Caucasians. This study also identified a specific genetic variant in the ABCG2 transporter gene that contributed to the between-population difference.¹⁶ Interestingly, at least one study that carefully matched subjects for transporter gene variants found no ethnic difference in drug exposure, suggesting that the population-level differences may be driven largely by the frequency of certain genetic variants rather than by something inherent to ethnicity itself.¹⁷

The practical upshot: if you are of East Asian or South Asian descent, 5 mg of rosuvastatin may give you the blood levels and cholesterol lowering that a 10 mg dose gives someone of European descent. Starting lower and titrating up based on lab results is a sensible approach, regardless of what population studies say about averages.

Drug Interactions That Effectively Raise Your Dose

Because rosuvastatin largely bypasses the liver’s main drug-metabolizing enzymes, it sidesteps many of the classic statin interactions. But it is heavily dependent on transporter proteins to get into and out of liver cells, and drugs that block those transporters can cause rosuvastatin levels to spike.

Cyclosporine, an immunosuppressant used after organ transplants, can increase rosuvastatin blood levels roughly five-fold by inhibiting transporters in both the liver and the intestine.¹⁸ This is why the rosuvastatin label caps the dose at 5 mg for anyone taking cyclosporine. HIV protease inhibitors raise rosuvastatin levels through a similar mechanism, primarily by blocking a transporter called BCRP in the gut and another called OATP1B1 in the liver.¹⁹

Gemfibrozil, a fibrate sometimes used alongside statins for people with both high LDL and high triglycerides, increased rosuvastatin blood levels by about 1.9-fold and peak levels by about 2.2-fold.²⁰ If you need a fibrate, fenofibrate is generally preferred because it does not significantly raise statin levels the way gemfibrozil does. In any of these scenarios, you could be taking 10 mg of rosuvastatin and effectively experiencing what 20 mg or more would do to your body, which matters for both efficacy and side-effect risk.

When Higher Doses Get Combined with Ezetimibe

For patients who cannot reach their LDL target on rosuvastatin alone, adding ezetimibe (a drug that blocks cholesterol absorption in the gut) is a common strategy. Studies of the combination using rosuvastatin 10 to 40 mg plus ezetimibe 10 mg have shown LDL reductions of up to 60 to 75%, with a good safety profile across a broad range of patients including those with existing cardiovascular disease.²¹ This combination often allows a patient to reach aggressive LDL targets without escalating to the 40 mg dose of rosuvastatin, which can be useful for people concerned about the kidney or diabetes signals at higher doses.

Higher-dose rosuvastatin also appears to have benefits beyond raw LDL lowering when it comes to particle quality. A trial comparing standard and high-dose rosuvastatin therapy found that the high-dose group had significantly greater reductions in small dense LDL particles and oxidized LDL, both of which are considered more atherogenic than ordinary LDL particles.²²

Morning or Evening Dosing

With short-acting statins like simvastatin, evening dosing matters because the liver’s cholesterol production peaks at night. Rosuvastatin’s long half-life makes this less relevant. A systematic review and meta-analysis comparing morning and evening statin regimens found that long-acting statins showed equivalent cholesterol-lowering regardless of when they were taken, aside from a tiny difference in LDL that was not clinically meaningful. The researchers concluded that long-acting statins should simply be taken at whatever time helps you remember to take them consistently.²³ If you are on rosuvastatin and someone tells you it must be taken at bedtime, they are applying advice meant for a different drug.

Rosuvastatin in Children and Adolescents

Pediatric use of rosuvastatin is approved, but only for children with familial hypercholesterolemia, a genetic condition that causes extremely high LDL from birth. The maximum pediatric dose is 20 mg rather than 40 mg. In a trial of children aged 6 to 17 with the heterozygous form, rosuvastatin 5, 10, and 20 mg reduced LDL by 38%, 45%, and 50%, respectively. At the highest allowed dose, 40% of children reached the treatment goal of LDL under 110 mg/dL. The drug was well tolerated with no apparent adverse effects on growth or sexual development.²⁴

For children with the rarer and more severe homozygous form, where both copies of the relevant gene are defective, rosuvastatin 20 mg still produced a meaningful LDL drop of about 22% (roughly 85 mg/dL in absolute terms), whether used alone or added to other treatments like ezetimibe or LDL apheresis.²⁵ These children often start with LDL levels above 400 or 500 mg/dL, so even a 22% reduction can be clinically valuable.

CoQ10 and Muscle Symptoms

Muscle aches are the most commonly reported side effect of statins, and they prompt many people to stop taking the drug or ask for a lower dose. One theory is that statins reduce levels of coenzyme Q10, a molecule involved in energy production inside muscle cells, and that supplementing it might help. A systematic review of randomized controlled trials found that CoQ10 supplementation improved statin-associated muscle symptoms across all the trials examined, sometimes alongside a reduced statin dose, and without notable side effects from the supplement itself.²⁶

That said, the evidence base here is still relatively thin, and many cardiologists consider the jury out on whether CoQ10 is genuinely helping or whether a placebo effect and dose adjustments are doing most of the work. If you are tolerating rosuvastatin 5 or 10 mg but struggling at 20 mg, a trial of CoQ10 supplementation is low-risk and inexpensive, but it should not replace a conversation with your prescriber about whether the higher dose is truly necessary for your risk level.